JP2024513485A - 免疫細胞活性を制御する方法 - Google Patents

免疫細胞活性を制御する方法 Download PDF

Info

Publication number
JP2024513485A
JP2024513485A JP2023561706A JP2023561706A JP2024513485A JP 2024513485 A JP2024513485 A JP 2024513485A JP 2023561706 A JP2023561706 A JP 2023561706A JP 2023561706 A JP2023561706 A JP 2023561706A JP 2024513485 A JP2024513485 A JP 2024513485A
Authority
JP
Japan
Prior art keywords
binding
cellular
immunotherapeutic agent
target antigen
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023561706A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024513485A5 (enExample
Inventor
シュリゲル，パトリック
バーデン，ジュリアン・アレクサンダー
リー，ジドゥオ
Original Assignee
バイオセプター （オースト） プロプライエタリー・リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2021901030A external-priority patent/AU2021901030A0/en
Application filed by バイオセプター （オースト） プロプライエタリー・リミテッド filed Critical バイオセプター （オースト） プロプライエタリー・リミテッド
Publication of JP2024513485A publication Critical patent/JP2024513485A/ja
Publication of JP2024513485A5 publication Critical patent/JP2024513485A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2023561706A 2021-04-08 2022-04-08 免疫細胞活性を制御する方法 Pending JP2024513485A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2021901030A AU2021901030A0 (en) 2021-04-08 Methods for controlling immune cell activity
AU2021901030 2021-04-08
PCT/AU2022/050311 WO2022213154A1 (en) 2021-04-08 2022-04-08 Methods for controlling immune cell activity

Publications (2)

Publication Number Publication Date
JP2024513485A true JP2024513485A (ja) 2024-03-25
JP2024513485A5 JP2024513485A5 (enExample) 2025-04-11

Family

ID=83544929

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023561706A Pending JP2024513485A (ja) 2021-04-08 2022-04-08 免疫細胞活性を制御する方法

Country Status (9)

Country Link
US (1) US20250282844A1 (enExample)
EP (1) EP4319793A4 (enExample)
JP (1) JP2024513485A (enExample)
CN (1) CN117157092A (enExample)
AU (1) AU2022253547A1 (enExample)
BR (1) BR112023020659A2 (enExample)
CA (1) CA3213042A1 (enExample)
MX (1) MX2023011807A (enExample)
WO (1) WO2022213154A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026507807A (ja) * 2023-03-08 2026-03-06 バイオセプター （オースト） プロプライエタリー・リミテッド 機能不全ｐ２ｘ７受容体に結合するためのキメラ抗原受容体

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528286A (ja) * 2001-01-17 2004-09-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020762A1 (en) * 2001-09-03 2003-03-13 Intreat Pty Limited Antibodies to non-functional p2x7receptor, diagnosis and treatment of cancers and other conditions
AU2009266430B2 (en) * 2008-07-04 2014-08-14 Biosceptre International Limited Anti- P2X7 peptides and epitopes
ES2699753T3 (es) * 2014-01-29 2019-02-12 Biontech Ag Mimótopos peptídicos de claudina 18.2 y sus usos
EP3484455A2 (en) * 2016-07-15 2019-05-22 Novartis AG Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
US10986601B2 (en) * 2017-07-26 2021-04-20 Panoramic Power Ltd. System and method for timing synchronization of a self-powered power sensor
CA3211323A1 (en) * 2021-03-11 2022-09-15 Patrick Schlegel Novel cell therapy system

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004528286A (ja) * 2001-01-17 2004-09-16 イントリート ピーティーワイ リミテッド 非機能性ｐ２ｘ７レセプター抗体、癌及びその他の容態の診断及び処置

Also Published As

Publication number Publication date
WO2022213154A1 (en) 2022-10-13
US20250282844A1 (en) 2025-09-11
EP4319793A4 (en) 2025-03-19
MX2023011807A (es) 2024-01-05
AU2022253547A1 (en) 2023-10-05
BR112023020659A2 (pt) 2023-12-05
CA3213042A1 (en) 2022-10-13
CN117157092A (zh) 2023-12-01
EP4319793A1 (en) 2024-02-14

Similar Documents

Publication Publication Date Title
US20230357717A1 (en) Cell secreted minibodies and uses thereof
US20240156866A1 (en) Multifunctional immune cell therapies
JP2021534762A (ja) 抗メソテリンキメラ抗原受容体（ｃａｒ）構築物及びその使用
US20240368282A1 (en) Methods and compositions for stimulating immune activity
CA3030837A1 (en) Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
IL262321B2 (en) Compositions and methods for selective protein expression
KR20170057298A (ko) Cd19에 특이적인 항체 및 키메라 항원 수용체
US20240252641A1 (en) Compositions and methods for tcr reprogramming using cd70 specific fusion proteins
JP2024510739A (ja) 新規な細胞治療システム
US20240307439A1 (en) Multifunctional immune cell therapies
CN114302733A (zh) 抗纽约食管鳞状细胞癌1(ny-eso-1)抗原结合蛋白及其使用方法
US20230416396A1 (en) Multispecific antigen binding molecules that bind cd38 and 4-1bb, and uses thereof
US20250282844A1 (en) Methods for controlling immune cell activity
TW202602909A (zh) 新穎介白素－７免疫結合物
TW202607028A (zh) 靶向ｅｍｒ２（ｃｄ３１２）及ｔ細胞受體ｔｒｂｖ１９之雙特異性抗體
BR122025006732A2 (pt) Receptor de antígeno quimérico (car), células engenheiradas, composição farmacêutica, ácido nucleico isolado, vetor e células expressando car
AU2024366504A1 (en) T-cell receptor-based multi-specific polypeptide molecule, and composition and use thereof
BR122025006733A2 (pt) Usos de células expressando receptor de antígeno quimérico (car) e de um adaptador
CN121127259A (zh) 用于结合功能障碍的p2x7受体的嵌合抗原受体
EA048926B1 (ru) Терапия на основе мультифункциональных иммунных клеток

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250403

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260610